Personalis is a contract research organization and genome-scale diagnostics services company specializing in genome guided medicine.
Personalis combines both the technology of sequencing and interpretation, with an extensive history of peer-reviewed publication and commercial success. It is providing an extensive molecular view of a patient’s tumor and characterizes its interplay with the immune system. It aids in the development of safer, effective precision cancer therapies, immunotherapies, and personalized medicines.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 27, 2021 | Post-IPO Equity | $150.10M | — | — | — | Detail |
Jun 20, 2019 | IPO | $134.66M | — | — | — | Detail |
Jan 13, 2015 | Series C | $33M | 4 | Lightspeed Venture Partners | — | Detail |
Oct 7, 2013 | Series B | $22M | 3 | Abingworth | — | Detail |
Aug 15, 2011 | Series A | $20M | 4 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lightspeed Venture Partners | Yes | Series C |
Abingworth | — | Series C |
Mohr Davidow Ventures | — | Series C |
Stanford University | — | Series C |